1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Issue 11 (November 2017) Authors: Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Avihingsanon, Anchalee; Ratanasuwan, Winai; Rojas, Evelyn; Rassool, Mohammed; Bloch, Mark; Vandekerckhove, Linos; Ruane, Peter; Yazdanpanah, Yazdan; Katlama, Christine; Xu, Xia; Rodgers, Anthony; East, Lilly; Wenni... Journal: Lancet Issue: Volume 4:Issue 11(2017) Page Start: e486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗